1. Number of participants with diabetes by trial Cholesterol Treatment Trialists' (CTT) Collaborators Lancet 2008;371:117-25

2. Baseline characteristics of participants presenting with or without diabetes Cholesterol Treatment Trialists' (CTT) Collaborators Lancet 2008;371:117-25

3. Proportional effects on cause-specific mortality per mmol/L reduction in LDL cholesterol in participants presenting with or without diabetes Cholesterol Treatment Trialists' (CTT) Collaborators Lancet 2008;371:117-25

4. Proportional effects on major vascular events per mmol/L reduction in LDL cholesterol in participants presenting with or without diabetes Cholesterol Treatment Trialists' (CTT) Collaborators Lancet 2008;371:117-25

5. Proportional effects on major vascular events per mmol/L reduction in LDL cholesterol in participants with and without diabetes by history of vascular disease Cholesterol Treatment Trialists' (CTT) Collaborators Lancet 2008;371:117-25

6. Proportional effects on major vascular events per mmol/L reduction in LDL cholesterol by baseline prognostic factors in participants with diabetes Cholesterol Treatment Trialists' (CTT) Collaborators Lancet 2008;371:117-25

7. Proportional effects on major vascular events per mmol/L reduction in LDL cholesterol by baseline lipid profi le in participants with diabetes Cholesterol Treatment Trialists' (CTT) Collaborators Lancet 2008;371:117-25

8. Proportional effects on major vascular events per mmol/L reduction in LDL cholesterol, by year, in participants with and without diabetes Cholesterol Treatment Trialists' (CTT) Collaborators Lancet 2008;371:117-25